| Name | Bicalutamide |
| Classes |
Anticancer/Antineoplastic Agent Hormonal Agent Antiandrogen Hormone |
| Diseases |
Cancer Prostate Cancer |
Bangla
EnglishBicalutamide
Bicalutamide is a nonsteroidal orally active antiandrogen drug. It exerts its antiandrogenic action by inhibiting androgen uptake and/or by inhibiting nuclear binding of androgen in target tissues or both. Prostatic carcinoma is known to be androgen-sensitive and responds to treatment that counteracts the effect of androgen and/or removes the source of androgen, e.g., castration.
Bicalutamide capsules are indicated for use in combination with LHRH-agonists for-
- Stage B2 -C Prostatic Carcinoma
- Stage D2 Metastatic Carcinoma
The recommended dose for Bicalutamide therapy in combination with an luteinizing hormone-releasing hormone (LHRH) analog is one 50 mg tablet once daily (morning or evening).
Adverse reactions that occurred in more than 10% of patients receiving Bicalutamide plus an LHRH-analog were:
- hot flashes
- pain (including general, back, pelvic and abdominal)
- asthenia
- constipation
- infection
- nausea
- peripheral edema
- dyspnea
- diarrhea
- hematuria
- nocturia
- anemia
- Severe hepatic injury and fatal hepatic failure have been observed. Monitor serum transaminase levels prior to starting treatment with Bicalutamide, at regular intervals for the first four months of treatment and periodically thereafter, and for symptoms or signs suggestive of hepatic dysfunction. Use Bicalutamide with caution in patients with hepatic impairment.
- Hemorrhage with Concomitant Use of Coumarin Anticoagulant. Closely monitor the Prothrombin Time (PT) and International Normalized Ratio (INR), and adjust the anticoagulant dose as needed.
- Gynecomastia and breast pain have been reported during treatment with Bicalutamide 150 mg when used as a single agent.
- Bicalutamide is used in combination with an LHRH agonist. LHRH agonists have been shown to cause a reduction in glucose tolerance in males. Consideration should be given to monitoring blood glucose in patients receiving Bicalutamide in combination with LHRH agonists.
- Monitoring Prostate Specific Antigen (PSA) is recommended. Evaluate for clinical progression if PSA increases.
Contraindication
Contraindicated in patients hypersensitive to Bicalutamide.
None known.
